Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
European Commission approves Tafinlar and Mekinist combination
September 13, 2015 Off

European Commission approves Tafinlar and Mekinist combination

By Dino Mustafić

The European Commission has approved the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with…

Strensiq in HPP patiens therapy get approval from European Commission
September 13, 2015 Off

Strensiq in HPP patiens therapy get approval from European Commission

By Dino Mustafić

Alexion Pharmaceuticals, Inc. announced on September 1, 2015, that the European Commission has approved Strensiq (asfotase alfa) for long-term enzyme replacement…

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray
June 15, 2015 Off

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

By Dino Mustafić

The National Institute on Drug Abuse (NIDA) has announced that Adapt Pharma Limited, a partner of Lightlake Therapeutics Inc., has started a rolling…

Cosentyx meets the primary endpoints
June 15, 2015 Off

Cosentyx meets the primary endpoints

By Dino Mustafić

Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms…

June 15, 2015 Off

Novartis: Long -term disease control for polycythemia vera patients treated with Jakavi

By Dino Mustafić

Novartis announced data that show majority of patients with polycythemia vera treated with Jakavi achieved long-term disease control. The company said…

June 7, 2015 Off

Xolair treats CSU patients better than placebo

By Dino Mustafić

Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients New analysis from…

Posts pagination

Previous 1 … 6,293 6,294

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence

January 29, 2026 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine